Bulletin of the National Research Centre (Jan 2024)
Rumex nervosus nanoparticles versus aqueous extract: introduction of novel immunomodulatory anti-inflammatory nano-preparation for management of paw oedema and gastritis in rats
Abstract
Abstract Background Rumex nervosus is abundant in East African and Arabian countries, and is used in curing gastrointestinal diseases as well as in wound healing. The current study intends to assess Rumex nervosus aqueous extract's anti-inflammatory benefits compared to its nanoparticles on rat paw edema and its gastric mucosal protection against ulceration. Materials and methods In-vitro cytotoxicity effects and antioxidant activity of Rumex nervosus nanoparticles versus aqueous extract were studied, followed by a pilot in vivo pharmacological study to determine the suitable dose of nanoparticles that would be used in the safety and efficacy studies in comparison with the aqueous extract. Its protective effects on arthritis and soft tissue inflammation were studied in rat paw edema and gastric ulcer models. Rumex nervosus extract (250 and 500 mg/kg) and nanoparticles (3.3 and 6.6 mg/kg) were given to four groups of rats orally before induction of paw oedema with subplantar 0.2 ml (1% w/v) formaldehyde or gastritis with oral ethanol 1 ml (70%), besides negative, positive control and reference groups. Results Paw volumes and gastric ulcer indices, as well as the anti-inflammatory and antioxidant parameters (kappa β, Paraoxonase1, and Malondialdehyde) that were measured in sera showed a marked reduction in groups treated with high doses of Rumex nervosus extract, and nanoparticles. Histopathologic and histochemical assessment of the stomachs confirmed the other investigations. All results were significant compared to positive control untreated groups. Conclusions Most studies demonstrated Rumex nervosus’s protective anti-inflammatory benefits with the superiority of large doses of nanoparticles, offering a promising natural solution for low cost against inflammation.
Keywords
